Skip to main content

Table 1 Summary of Baseline Characteristics

From: Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies

Characteristic

Study

 

LYCS

(n = 105)

S012

(n = 212)

S013

(n = 21)

All

(N = 338)

Gender, male, n (%)

76 (72.4)

157 (74.1)

16 (76.2)

249 (73.7)

Age

9.3 (0.08)

8.5 (0.11)

8.0 (0.28)

8.7 (0.08)

ADHD subtype, n (%)

    

Combined

74 (70.5)

166 (78.3)

6 (28.6)

246 (72.8)

Inattentive

31 (29.5)

43 (20.3)

15 (71.4)

89 (26.3)

Hyperactive/impulsive

0 (0.0)

3 (1.4)

0 (0.0)

3 (0.9)

Stimulant-naïve, n (%)

105 (100.0)

116 (54.7)

8 (38.1)

229 (67.8)

ADHDRS-IV-PI

37.0 (0.84)

40.5 (0.52)

35.9 (1.13)

39.1 (0.43)

CGI-ADHD-S

4.6 (0.08)

4.8 (0.06)

4.9 (0.10)

4.8 (0.05)

  1. ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale Parent Version: Investigator Administered and Scored; CGI-ADHD-S = Clinical Global Impression of ADHD Severity.
  2. Mean (SE) or numbers (%).